Skip to content Skip to footer

News

January 15, 2014 | TruPharma Supports Strides Pharma., Inc. with the Launch of products on the Strides label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement entered in September 2013, it assisted Strides Pharma., Inc. with the establishment of a commercial platform for the US market. This infrastructure allowed Strides to launch its first four products in the US market on the Strides label. TruPharma continues to support Strides with the sales, marketing and distribution of these existing products, and will launch additional products for Strides over the next several years.

March 15, 2014 | TruPharma Supports Amerigen Pharmaceuticals with the Launch of its Carbidopa 25mg Tablets (a generic equivalent of Valeant’s Lodosyn®) on the Amerigen label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement entered in November 2013, it has worked with Amerigen Pharmaceuticals to establish that company’s commercial platform, and to launch its recently-approved Carbidopa 25mg Tablets (a generic equivalent of Valeant’s Lodosyn®) on an Amerigen label. TruPharma continues to work with Amerigen to manage the sales, marketing and distribution of the product.

July 1, 2014 | TruPharma Announces the Appointment of Chief Sales & Marketing Officer

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that Steven Randazzo has joined the company as a partner and will serve as TruPharma’s Chief Sales & Marketing Officer. Mr. Randazzo has over twenty years of sales and marketing experience, having served in various positions with Anchen Pharmaceuticals, KV/Ethex Pharmaceuticals, and most recently, Lupin Pharmaceuticals.

February 2, 2015 | TruPharma Supports Orchid Pharma, Inc. with Its Sales & Marketing Needs for the US Market

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement entered in January 2015, Orchid Pharma, Inc. has engaged TruPharma to manage the day-to-day sales & marketing of its existing portfolio of approximately fifteen FDA-approved ANDA products, as well as a pipeline of pending ANDA products. TruPharma will support its existing US operation with the sales, marketing and distribution of these products on the Orchid label.

May 20, 2015 | TruPharma In-Licenses Pending ANDA Products

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to two separate agreements with its collaboration partners, it has in-licensed products that will be sold on the TruPharma label. The products and partners are confidential pending FDA approval of the pending ANDAs. TruPharma expects the products to be approved and launched in 2016.

September 9, 2015 | TruPharma Enters Agreement to Support a Fourth Company with Its Sales & Marketing Needs for the US Market

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement entered as of September 9, 2015, it has agreed to support a fourth company with the launch of its commercial operation for the US market. TruPharma’s partner, which shall remain confidential pending the launch of its first product, has an extensive pipeline of pending ANDAs, and expects the first products on this new label to launch in mid-2016.

November 18, 2015 | TruPharma Enters Co-Development & Marketing Agreement

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement with a collaboration partner entered November 18, 2015, it has agreed to co-develop a portfolio of niche products that will be sold on the TruPharma label. The products and the partner are confidential pending FDA approval of the ANDAs. TruPharma expects the first two products that are subject to the agreement to be submitted to FDA in 2016.

December 18, 2015 | TruPharma Enters Multiple-Product Development and Marketing Agreement with Pharmadax USA, Inc.

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to a December 18, 2015 agreement with Pharmadax USA, Inc. (a subsidiary of Pharmadax, Inc.), it has agreed to co-develop and market a portfolio of niche products that will be sold on the TruPharma label. The current product portfolio consists of multiple products, some of which are pending with FDA and others are to be developed in the next eighteen months. The agreement contemplates that additional products will be added for future development. TruPharma expects the first of the pending ANDA products to receive FDA approval and to be launched in 2016.

April 1, 2016 | TruPharma In-Licenses Two Approved ANDA Products

TAMPA, Florida – TruPharma, LLC (TruPharma) announced that pursuant to two separate agreements with different supply partners, it has licensed two approved generic products, and plans to launch the products in 2016.

May 19, 2016 | TruPharma Adds Two Co-Development Projects to Existing Master Collaboration Agreement

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an existing agreement entered in 2015 with a collaboration partner, it has added two products that will be developed and are expected to be submitted to the FDA for review in 2017. The products and the partner are confidential pending FDA approval of the ANDAs.

July 6, 2016 | TruPharma Announces the Appointment of Corporate Controller

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that Henry “Hank” Daude has joined the company and will serve as TruPharma’s first Corporate Controller. Mr. Daude has over thirty years of finance and accounting experience in the pharmaceutical industry, having served in various positions with Ethex Corporation/KV Pharmaceutical, and most recently at Virtus Pharmaceuticals, LLC.

August 15, 2016 | TruPharma Launches Glyburide Tablets on the TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Glyburide Tablets USP on the TruPharma label. The product is available in 1.25 mg, 2.5 mg and 5 mg strengths. The FDA-approved product is being supplied to TruPharma pursuant to an agreement with Pharmadax USA, Inc. (a subsidiary of Pharmadax, Inc.).

September 1, 2016 | TruPharma Announces the Appointment of Vice President of National Accounts

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that Nick Giffen has joined the company and will serve as TruPharma’s Vice President of National Accounts. Mr. Giffen has over ten years of sales and account management experience in the healthcare industry, having served in various positions with KV Pharmaceutical, Ferris Manufacturing Corporation, Acella Pharmaceutical, and most recently at BioComp Pharmaceutical.

September 19, 2016 | TruPharma Launches Venlafaxine Tablets on the TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Venlafaxine Tablets on the TruPharma label. The product is available in 25 mg, 37.5 mg, 50 mg, 75 mg, and 100 mg strengths. The FDA-approved product is being supplied to TruPharma pursuant to an agreement with Yaopharma Co., Ltd.

February 22, 2017 | TruPharma Enters Co-Development & Marketing Agreement

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement with a collaboration partner entered February 22, 2017, it has agreed to co-develop two more niche injectable products that will be sold on the TruPharma label. The products and the partner are confidential pending FDA approval of the ANDAs. TruPharma expects the products under development will be submitted to FDA in the first half of 2018.

March 3, 2017 | TruPharma Launches Cyproheptadine Hydrochloride Tablets on the TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it launched Cyproheptadine Hydrochloride Tablets on the TruPharma label. The product is available in a 4 mg strength. The FDA-approved product is being supplied to TruPharma pursuant to an agreement with Appco Pharma LLC.

March 7, 2017 | TruPharma Expands and Extends its Agreement to Support Amerigen Pharmaceuticals with its Front End Commercial Operation

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an amendment to its existing agreement with Amerigen Pharmaceuticals, it has agreed to continue sales and marketing of products on the Amerigen label. The agreement now covers three products currently on the market, and five other product applications on file with the FDA.

April 4, 2017 | TruPharma In-Licenses Several Approved ANDA Products

TAMPA, Florida – TruPharma, LLC (TruPharma) announced that pursuant to a master agreement with a collaboration partner, it has in-licensed five products that will be sold on the TruPharma label. The products and partner are confidential pending launch. TruPharma expects two of the products to launch in 2017, and the others to launch in 2018.

May 10, 2017 | TruPharma Launches Quetiapine Fumarate ER Tablets on the TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Quetiapine Fumarate ER Tablets on the TruPharma label. FDA has determined that this product is therapeutically equivalent to the reference listed drug (RLD), SEROQUEL® XR Tablets of AstraZeneca Pharmaceuticals LP (AstraZeneca). The product is available in 50 mg (base), 150 mg (base), 200 mg (base), 300 mg (base), and 400 mg (base) strengths. The FDA-approved product is being supplied to TruPharma pursuant to an agreement with Pharmadax USA, Inc. (a subsidiary of Pharmadax, Inc.). SEROQUEL® is a registered trademark of AstraZeneca UK Limited.

June 6, 2017 | TruPharma Launches Lamotrigine Extended Release Tablets on the TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Lamotrigine Extended Release Tablets, an AB-rated generic version of GlaxoSmithKline’s LAMICTAL® XR. The FDA-approved product is being supplied to TruPharma pursuant to an agreement with Handa Pharmaceuticals, LLC, (a subsidiary of Handa Pharmaceuticals, Inc.). LAMICTAL® is a registered trademark of GlaxoSmithKline.

August 1, 2017 | TruPharma Launches Cyclobenzaprine HCl Tablets and Clonidine HCl Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Cyclobenzaprine Hydrochloride Tablets 5 mg & 10 mg, and Clonidine Hydrochloride Tablets 0.1 mg, 0.2 mg & 0.3 mg on the TruPharma label. The FDA-approved products are being supplied to TruPharma pursuant to a master agreement with Frontida BioPharm, Inc., which includes additional products that TruPharma expects to launch in the next eighteen months.

September 29, 2017 | TruPharma In-Licenses Two Pending ANDA Products

TAMPA, Florida – TruPharma, LLC (TruPharma) announced that pursuant to a master agreement with a collaboration partner, it has in-licensed two pending ANDA products that will be sold on the TruPharma label. The products and partner are confidential pending launch. TruPharma expects the products to launch in 2018.

November 8, 2017 | TruPharma Commences Sales and Distribution of Versacloz™ Brand Clozapine Oral Suspension on Behalf of Tasman Pharma, Inc.

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement with Tasman Pharma, Inc. (Tasman), it has commenced sales and distribution of Versacloz™ Brand (Clozapine, USP) Oral Suspension, 50mg/mL. Tasman recently acquired the approved NDA for Versacloz™ from Jazz Pharmaceuticals, and upon closing of that transaction, appointed TruPharma as the exclusive distributor of Versacloz™. With this arrangement, TruPharma has expanded its platform to include distribution of branded pharmaceutical products through purchase and supply agreements with the three major wholesalers, other buying groups, and the federal government.

March 16, 2018 | TruPharma In-Licenses Five ANDA Products

TAMPA, Florida – TruPharma, LLC (TruPharma) announced that pursuant to a master agreement with a collaboration partner, it has in-licensed five ANDA products that will be sold on the TruPharma label. The products and partner are confidential pending launch. TruPharma expects the products to launch in 2018.

May 1, 2018 | TruPharma Launches Baclofen Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Baclofen 5 mg, 10 mg, and 20 mg Tablets on the TruPharma label. The FDA-approved products are being supplied to TruPharma pursuant to a master agreement with Rubicon Research Private Limited. Significantly, Rubicon holds the only FDA approval for a 5 mg Baclofen Tablet product, and TruPharma will be the single source supplier to the market for this item.

May 15, 2018 | TruPharma Launches Additional Strength of Cyclobenzaprine HCl Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Cyclobenzaprine Hydrochloride 7.5 mg Tablets on the TruPharma label. This limited competition item is being supplied to TruPharma pursuant to a master agreement with Rubicon Research Private Limited. TruPharma previously launched the 5 mg, 10, mg tablet products.

July 1, 2018 | TruPharma Launches Sildenafil Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Sildenafil 25 mg, 50 mg, and 100 mg Tablets on the TruPharma label. The FDA-approved products are generic equivalents to Pfizer’s VIAGRA® branded product. TruPharma’s product is being supplied to TruPharma pursuant to a master agreement with Rubicon Research Private Limited.

December 6, 2018 | TruPharma Launches Metoprolol Tartrate Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Metoprolol Tartrate 25 mg, 50 mg, and 100 mg Tablets on the TruPharma label. The FDA-approved products are being supplied to TruPharma pursuant to a master agreement with Rubicon Research Private Limited.

January 7, 2019 | TruPharma Launches Sildenafil Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Sildenafil 20 mg Tablets on the TruPharma label. The FDA-approved products are generic equivalents to Pfizer’s REVATIO® branded product. TruPharma’s product is being supplied to TruPharma pursuant to a master agreement with Rubicon Research Private Limited.

June 17, 2019 | TruPharma Launches Oxybutynin Chloride Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Oxybutynin Chloride 5 mg Tablets on the TruPharma label. The FDA-approved product is being supplied to TruPharma pursuant to a master agreement with Tulex Pharmaceuticals, LLC.

July 9, 2019 | TruPharma Launches Bisoprolol Fumarate Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Bisoprolol Fumarate 5 mg & 10 mg Tablets on the TruPharma label. This limited source item was recently on the FDA’s Drug Shortage list. The FDA-approved product is being supplied to TruPharma pursuant to a master agreement with Frontida BioPharm, Inc.

August 21, 2019 | TruPharma Launches First FDA-Approved Generic Triamterene Capsules on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched the first ANDA generic Triamterene 50 mg and 100 mg Capsules in collaboration with Agnitio Inc. Agnitio is supplying this limited competition item exclusively to TruPharma pursuant to a master agreement. Agnitio was the first company to receive FDA approval of a product determined to be bioequivalent and therapeutically equivalent to DYRENIUM® Capsules, 50 mg and 100 mg of Concordia Pharmaceuticals, Inc.

October 15, 2019 | TruPharma Launches Clotrimazole Topical Solution on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Clotrimazole 1% Topical Solution in collaboration with Tasman Pharma, Inc. (Tasman). The FDA-approved product is a generic equivalent to LOTRIMIN® branded product. Tasman is supplying this item to TruPharma pursuant to a master agreement.

November 1, 2019 | TruPharma Launches Additional Strengths of Metoprolol Tartrate Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Metoprolol Tartrate 37.5 mg and 75 mg Tablets on the TruPharma label. The FDA-approved products are being supplied to TruPharma pursuant to a master agreement with Rubicon Research Private Limited. Significantly, Rubicon is one of only two companies to hold an FDA approval for these two strengths of Metoprolol Tartrate Tablets.

February 3, 2020 | TruPharma Launches the First Tramadol 100 mg Tablet Product on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Tramadol 100mg Tablets on the TruPharma label. The FDA-approved products are being supplied to TruPharma pursuant to a master agreement with Rubicon Research Private Limited. Significantly, Rubicon holds the only FDA approval for a 100 mg strength Tramadol Tablet product, and TruPharma will be the single source supplier to the market for this item.

February 10, 2020 | TruPharma Launches Midodrine Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Midodrine 5mg and 10 mg Tablets on the TruPharma label. The FDA-approved products are being supplied to TruPharma pursuant to a master agreement with Rubicon Research Private Limited.

May 1, 2020 | TruPharma Launches Ethacrynic Acid Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Ethacrynic Acid 25 mg Tablets in collaboration with Agnitio Inc. The FDA-approved product is a generic equivalent to EDECRIN® branded product. Agnitio is supplying this item to TruPharma pursuant to a master agreement.

May 29, 2020 | TruPharma Signs a Sales and Distribution Agreement with Acrux DDS

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has entered a 10-year exclusive sales, marketing and distribution agreement with Acrux DDS. Subject to FDA filing and approval, TruPharma will sell and distribute six unnamed products from Acrux’s development portfolio.

June 5, 2020 | TruPharma Launches Acetic Acid Solution on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Acetic Acid 2% Solution Otic Drops in collaboration with Saptalis Pharmaceuticals, LLC. The FDA-approved product is a generic equivalent to the VORSOL® branded product. Saptalis is supplying this item to TruPharma pursuant to an exclusive Sales, Marketing & Distribution Agreement entered earlier this year.

June 30, 2020 | TruPharma Launches Ramelteon Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Ramelteon 8 mg Tablets in collaboration with i3 Pharmaceuticals, LLC. The FDA-approved product is a generic equivalent to the ROZEREM® branded product. i3 is supplying this item to TruPharma pursuant to an exclusive Sales, Marketing & Distribution Agreement entered earlier this year.

September 1, 2020 | TruPharma Launches Clomipramine HCl Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Clomipramine Hydrochloride 25 mg, 50 mg and 100 mg Tablets in collaboration with Tulex Pharmaceuticals, LLC. The FDA-approved product is a generic equivalent to the ANAFRANIL® branded product. Tulex is supplying this item to TruPharma pursuant to a master agreement.

September 25, 2020 | TruPharma Launches Aminocaproic Acid Solution on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Aminocaproic Acid .25g/mL Oral Solution in collaboration with Tulex Pharmaceuticals, LLC. The FDA-approved product is a generic equivalent to the AMICAR® branded product. Tulex is supplying this item to TruPharma pursuant to a master agreement.

October 1, 2020 | TruPharma Launches Chlorzoxazone Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Chlorzoxazone 375 mg and 750 mg Tablets in collaboration with i3 Pharmaceuticals, LLC. i3 is supplying this item to TruPharma pursuant to an exclusive Sales, Marketing & Distribution Agreement entered earlier this year.

October 7, 2020 | TruPharma Launches Oxazepam Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Oxazepam 10 mg, 15 mg, and 30 mg Tablets on the TruPharma label. This limited source item was recently on the FDA’s Drug Shortage list. The FDA-approved product is being supplied to TruPharma pursuant to a master agreement with Frontida BioPharm, Inc.

January 15, 2021 | TruPharma Supports Rubicon Private Limited with the Launch of products on its Advagen label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement entered in 2018, it assisted Rubicon Private Limited (Rubicon) with the establishment of a commercial platform that allowed it to launch its first products in the US market on a label held by its affiliate, Advagen Pharma Ltd. (Advagen).

July 1, 2021 | TruPharma Launches Acetazolamide Tablets on the TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it launched Acetazolamide Tablets on the TruPharma label. The product is available in 125mg and 250mg strengths. The FDA-approved product is being supplied to TruPharma pursuant to an agreement with Appco Pharma LLC.

March 1, 2022 | TruPharma, LLC Announces Approval and Launch of Apomorphine Hydrochloride Cartridges, 30 mg/3 mL (10 mg/mL), the First Generic Version of APOKYN® Cartridges

TruPharma, LLC (“TruPharma”), together with its development and commercial partner Sage Chemical, Inc. (“Sage”), announces that the U.S. Food and Drug Administration (FDA) has approved Sage’s Abbreviated New Drug Application (ANDA) for generic apomorphine hydrochloride cartridges, 30 mg/3 mL (10 mg/mL). FDA approved the generic cartridge product upon a determination that it is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), APOKYN®1 branded Injection, 30 mg/3 mL (10 mg/mL), Single-Patient-Use cartridge, of MDD US Operations, LLC, which is used by injection, as needed, to treat loss of control of body movements in people with advanced Parkinson’s disease (PD). Sage is the “first approved applicant” for Apomorphine Hydrochloride Injection, 30 mg/3 mL (10 mg/mL), Single-Patient-Use glass cartridge for use with a reusable pen injector (APOKYN® Pen). FDA therefore determined that Sage is eligible for 180 days of Competitive Generic Therapy (CGT) exclusivity. TruPharma has commenced commercial marketing of Sage’s approved generic cartridge product. TruPharma will continue supplying apomorphine hydrochloride cartridges to the trade, but in limited quantities due to current manufacturing and supply chain constraints. 1APOKYN is a registered trademark of BRITUSWIP. US WorldMeds, LLC is the licensee and distributor of APOKYN.

March 11, 2022 | TruPharma Launches Levocarnitine Oral Solution

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it launched Levocarnitine 1 gram/10 mL Oral Solution. The product is available in 118 mL bottles. The FDA-approved product is therapeutically equivalent and AA-rated to CARNITOR branded Levocarnitine Oral Solution, and is being supplied to TruPharma pursuant to an agreement with Saptalis Pharmaceuticals, LLC.

March 11, 2022 | TruPharma Launches Metformin HCl Oral Solution in a Unit Dose Presentation

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it launched Metformin Hydrochloride 500mg/5mL Oral Solution in a Unit Dose Cup presentation. The FDA-approved product is therapeutically equivalent and AA-rated to RIOMET branded Metformin HCl Oral Solution, and is being supplied to TruPharma pursuant to an agreement with Saptalis Pharmaceuticals, LLC.

April 13, 2022 | TruPharma Launches Betamethasone Dipropionate Topical Ointment

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it launched Betamethasone Dipropionate Eq. 0.05% Base Topical Ointment. The product is available in 15 gram and 45 gram tubes. The FDA-approved product is being supplied to TruPharma pursuant to an agreement with Tasman Pharma, Inc.